Search

Your search keyword '"Debra A Cockayne"' showing total 2 results
Start Over Author "Debra A Cockayne" Publisher public library of science (plos)
2 results on '"Debra A Cockayne"'

1. Systemic biomarkers of neutrophilic inflammation, tissue injury and repair in COPD patients with differing levels of disease severity.

Author

Debra A Cockayne, Donavan T Cheng, Benjamin Waschki, Sriram Sridhar, Palanikumar Ravindran, Holly Hilton, Galina Kourteva, Hans Bitter, Sreekumar G Pillai, Sudha Visvanathan, Kai-Christian Müller, Olaf Holz, Helgo Magnussen, Henrik Watz, and Jay S Fine

Subjects
Medicine, Science
Abstract

The identification and validation of biomarkers to support the assessment of novel therapeutics for COPD continues to be an important area of research. The aim of the current study was to identify systemic protein biomarkers correlated with measures of COPD severity, as well as specific protein signatures associated with comorbidities such as metabolic syndrome. 142 protein analytes were measured in serum of 140 patients with stable COPD, 15 smokers without COPD and 30 non-smoking controls. Seven analytes (sRAGE, EN-RAGE, NGAL, Fibrinogen, MPO, TGF-α and HB-EGF) showed significant differences between severe/very severe COPD, mild/moderate COPD, smoking and non-smoking control groups. Within the COPD subjects, univariate and multivariate analyses identified analytes significantly associated with FEV(1), FEV(1)/FVC and DLCO. Most notably, a set of 5 analytes (HB-EGF, Fibrinogen, MCP-4, sRAGE and Sortilin) predicted 21% of the variability in DLCO values. To determine common functions/pathways, analytes were clustered in a correlation network by similarity of expression profile. While analytes related to neutrophil function (EN-RAGE, NGAL, MPO) grouped together to form a cluster associated with FEV(1) related parameters, analytes related to the EGFR pathway (HB-EGF, TGF-α) formed another cluster associated with both DLCO and FEV(1) related parameters. Associations of Fibrinogen with DLCO and MPO with FEV(1)/FVC were stronger in patients without metabolic syndrome (r = -0.52, p = 0.005 and r = -0.61, p = 0.023, respectively) compared to patients with coexisting metabolic syndrome (r = -0.25, p = 0.47 and r = -0.15, p = 0.96, respectively), and may be driving overall associations in the general cohort. In summary, our study has identified known and novel serum protein biomarkers and has demonstrated specific associations with COPD disease severity, FEV(1), FEV(1)/FVC and DLCO. These data highlight systemic inflammatory pathways, neutrophil activation and epithelial tissue injury/repair processes as key pathways associated with COPD.

Published
2012
Full Text
View/download PDF

2. Systemic biomarkers of neutrophilic inflammation, tissue injury and repair in COPD patients with differing levels of disease severity

Author

Holly Hilton, Debra A. Cockayne, Benjamin Waschki, Sreekumar G. Pillai, Kai-Christian Müller, Palanikumar Ravindran, Jay S. Fine, Sudha Visvanathan, Helgo Magnussen, Galina Kourteva, Henrik Watz, Sriram Sridhar, Donavan T. Cheng, Olaf Holz, Hans Bitter, and Publica

Subjects
Male, Pulmonology, Chronic Obstructive Pulmonary Diseases, Epidemiology, Receptor for Advanced Glycation End Products, Comorbidity, Fibrinogen, Gastroenterology, Pulmonary function testing, Cohort Studies, Pulmonary Disease, Chronic Obstructive, DLCO, Forced Expiratory Volume, Granulocyte Colony-Stimulating Factor, Pathology, Receptors, Immunologic, Metabolic Syndrome, COPD, Multidisciplinary, S100 Proteins, Smoking, Acute-phase protein, respiratory system, Lipocalins, Intercellular Signaling Peptides and Proteins, Regression Analysis, Medicine, Female, Research Article, Heparin-binding EGF-like Growth Factor, medicine.drug, medicine.medical_specialty, Recombinant Fusion Proteins, Science, Immunology, FEV1/FVC ratio, Lipocalin-2, Diagnostic Medicine, Proto-Oncogene Proteins, Internal medicine, medicine, Humans, Biology, Aged, Inflammation, business.industry, S100A12 Protein, Immunity, chronic obstructive Pulmonary disease, Immunologic Subspecialties, Transforming Growth Factor alpha, medicine.disease, respiratory tract diseases, Systemic inflammatory response syndrome, Biomarker Epidemiology, biochemical marker, Multivariate Analysis, Pulmonary Diffusing Capacity, Clinical Immunology, Interleukin-3, Metabolic syndrome, business, Pulmonary Immunology, Biomarkers, General Pathology, Acute-Phase Proteins
Abstract

The identification and validation of biomarkers to support the assessment of novel therapeutics for COPD continues to be an important area of research. The aim of the current study was to identify systemic protein biomarkers correlated with measures of COPD severity, as well as specific protein signatures associated with comorbidities such as metabolic syndrome. 142 protein analytes were measured in serum of 140 patients with stable COPD, 15 smokers without COPD and 30 non-smoking controls. Seven analytes (sRAGE, EN-RAGE, NGAL, Fibrinogen, MPO, TGF-α and HB-EGF) showed significant differences between severe/very severe COPD, mild/moderate COPD, smoking and non-smoking control groups. Within the COPD subjects, univariate and multivariate analyses identified analytes significantly associated with FEV(1), FEV(1)/FVC and DLCO. Most notably, a set of 5 analytes (HB-EGF, Fibrinogen, MCP-4, sRAGE and Sortilin) predicted 21% of the variability in DLCO values. To determine common functions/pathways, analytes were clustered in a correlation network by similarity of expression profile. While analytes related to neutrophil function (EN-RAGE, NGAL, MPO) grouped together to form a cluster associated with FEV(1) related parameters, analytes related to the EGFR pathway (HB-EGF, TGF-α) formed another cluster associated with both DLCO and FEV(1) related parameters. Associations of Fibrinogen with DLCO and MPO with FEV(1)/FVC were stronger in patients without metabolic syndrome (r = -0.52, p = 0.005 and r = -0.61, p = 0.023, respectively) compared to patients with coexisting metabolic syndrome (r = -0.25, p = 0.47 and r = -0.15, p = 0.96, respectively), and may be driving overall associations in the general cohort. In summary, our study has identified known and novel serum protein biomarkers and has demonstrated specific associations with COPD disease severity, FEV(1), FEV(1)/FVC and DLCO. These data highlight systemic inflammatory pathways, neutrophil activation and epithelial tissue injury/repair processes as key pathways associated with COPD.

Published
2012

Catalog

Books, media, physical & digital resources
See catalog results